130 related articles for article (PubMed ID: 22239432)
21. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
[TBL] [Abstract][Full Text] [Related]
22. Human anti-mouse IgM and IgG responses in ovarian cancer patients after radioimmunotherapy with 90Y-muHMFG1.
Oei AL; Sweep FC; Geurts-Moespot A; van Tienoven D; Von Mensdorff-Pouilly S; Thomas CM; Massuger LF
Anticancer Res; 2008; 28(5A):2721-5. PubMed ID: 19035301
[TBL] [Abstract][Full Text] [Related]
23. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.
Crow DM; Williams L; Colcher D; Wong JY; Raubitschek A; Shively JE
Bioconjug Chem; 2005; 16(5):1117-25. PubMed ID: 16173788
[TBL] [Abstract][Full Text] [Related]
24. Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177Lu.
Mohsin H; Jia F; Bryan JN; Sivaguru G; Cutler CS; Ketring AR; Miller WH; Simón J; Frank RK; Theodore LJ; Axworthy DB; Jurisson SS; Lewis MR
Bioconjug Chem; 2011 Dec; 22(12):2444-52. PubMed ID: 22053899
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy tolerance after radioimmunotherapy with 90Y-CC49 monoclonal antibody in patients with advanced non-small cell lung cancer: clinical effects and hematologic toxicity.
Robert F; Busby EM; LoBuglio AF
Cancer Biother Radiopharm; 2003 Jun; 18(3):317-25. PubMed ID: 12954119
[TBL] [Abstract][Full Text] [Related]
26. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
28. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.
Stillebroer AB; Boerman OC; Desar IM; Boers-Sonderen MJ; van Herpen CM; Langenhuijsen JF; Smith-Jones PM; Oosterwijk E; Oyen WJ; Mulders PF
Eur Urol; 2013 Sep; 64(3):478-85. PubMed ID: 22980441
[TBL] [Abstract][Full Text] [Related]
29. Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.
Rogers BE; Roberson PL; Shen S; Khazaeli MB; Carpenter M; Yokoyama S; Brechbiel MW; LoBuglio AF; Buchsbaum DJ
Cancer Biother Radiopharm; 2005 Oct; 20(5):502-13. PubMed ID: 16248766
[TBL] [Abstract][Full Text] [Related]
30. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
31. A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.
Wong JY; Chu DZ; Williams LE; Liu A; Zhan J; Yamauchi DM; Wilczynski S; Wu AM; Yazaki PJ; Shively JE; Leong L; Raubitschek AA
Cancer Biother Radiopharm; 2006 Apr; 21(2):88-100. PubMed ID: 16706629
[TBL] [Abstract][Full Text] [Related]
32. Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma.
Divgi CR; Scott AM; Gulec S; Broussard EK; Levy N; Young C; Capitelli P; Daghighian F; Williams JM; Finn RD
Clin Cancer Res; 1995 Dec; 1(12):1503-10. PubMed ID: 9815950
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts.
Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27196891
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma.
Mahé MA; Fumoleau P; Fabbro M; Guastalla JP; Faurous P; Chauvot P; Chetanoud L; Classe JM; Rouanet P; Chatal JF
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3249s-3253s. PubMed ID: 10541371
[TBL] [Abstract][Full Text] [Related]
35. Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model.
Frost SH; Bäck T; Chouin N; Hultborn R; Jacobsson L; Elgqvist J; Jensen H; Albertsson P; Lindegren S
Cancer Biother Radiopharm; 2013 Mar; 28(2):108-14. PubMed ID: 23230896
[TBL] [Abstract][Full Text] [Related]
36. Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelating Polymers Complexed to
Aghevlian S; Cai Z; Lu Y; Hedley DW; Winnik MA; Reilly RM
Mol Pharm; 2019 Feb; 16(2):768-778. PubMed ID: 30589553
[TBL] [Abstract][Full Text] [Related]
37. Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft.
Kraeber-Bodéré F; Saï-Maurel C; Campion L; Faivre-Chauvet A; Mirallié E; Chérel M; Supiot S; Barbet J; Chatal JF; Thédrez P
Mol Cancer Ther; 2002 Feb; 1(4):267-74. PubMed ID: 12467222
[TBL] [Abstract][Full Text] [Related]
38. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis.
Nicholson S; Gooden CS; Hird V; Maraveyas A; Mason P; Lambert HE; Meares CF; Epenetos AA
Oncol Rep; 1998; 5(1):223-6. PubMed ID: 9458326
[TBL] [Abstract][Full Text] [Related]
39. Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy.
Gokhale AS; Mayadev J; Pohlman B; Macklis RM
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):194-201. PubMed ID: 16111589
[TBL] [Abstract][Full Text] [Related]
40. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]